Objective: The objective of this study was to assess 1-year safety, efficacy, and invasiveness outcomes of endovascular stent grafting of symptomatic long lesions ($10 cm) in the superficial femoral artery (SFA) as a substitute for above-knee open bypass surgery.
recommendation has come under increased scrutiny because of improved outcomes after endovascular procedures due to advanced techniques and technology. 3, 4 In 2015, TASC published an update detailing important progress in endovascular therapy since the original guideline publication 5 and recognizes the global transition toward the "endovascular first" approach. 6, 7 Society for Vascular Surgery 2015 updated guidelines for PAD treatment emphasize using autologous vein grafts for bypass surgery, but that document applies only to patients with claudication or asymptomatic PAD. 8 Open bypass is relatively invasive, consumes considerable health care resources during surgery and rehabilitation, 9, 10 and carries risk of serious adverse events (AEs), including wound and graft infection, bleeding, and lymphedema. 11 Increasing evidence indicates that percutaneous techniques may provide functional outcomes similar to open bypass surgery for treating complex TASC C and D disease in the SFA while minimizing the invasiveness and side effects of open surgery. 12, 13 Of the rapidly advancing endovascular devices, selfexpanding stent grafts most closely mimic the structure of open bypass grafts. Stent grafts exclude intraluminal ingrowth of the diseased vessel wall to re-create a patent blood flow conduit, similar to bypass grafts. A 2010 report from a single-center randomized controlled trial (RCT) comparing SFA stent grafting vs synthetic above-knee bypass indicated comparable patency outcomes in TASC II C and D lesions 12 ; however, these data have not been validated in multicenter trials. In Japan, open bypass has historically been regarded as the standard procedure for treating long and complicated SFA lesions. This study is the first prospective, multicenter trial to evaluate the safety, invasiveness, and effectiveness of stent grafts in a Japanese population with SFA lesions averaging >20 cm in length.
METHODS
Study design. Study cases were performed between April 2012 and August 2013 by endovascular specialists at 15 study sites in Japan who had prior experience with the study device or undertook at least one training case with the device before enrolling subjects. All subjects provided written informed consent. The study protocol was approved by the Institutional Review Boards of all participating institutions and conformed to Declaration of Helsinki tenets and the Japanese Ministerial Ordinance on Good Clinical Practice for Medical Devices.
Inclusion and exclusion criteria. Clinical inclusion criteria were the following: age $20 years; study limb Rutherford 14 category 2 to 5 (eligibility of Rutherford 5 patients with active infection was reviewed by a threeinvestigator case-conference committee [CCC] ); target limb ankle-brachial index (ABI) #0.9 or toe-brachial index (TBI) #0.5; life expectancy >2 years; and surgical bypass candidate.
Angiographic inclusion criteria were the following: one de novo or restenotic SFA lesion with total length $10 cm, with at least one region of focal luminal narrowing $50%; lesion in region beginning 1 cm below SFA origin and ending 1 cm above intercondylar notch; proximal and distal reference vessel diameters of 4.0 to 7.5 mm; at least one patent tibial or peroneal artery to the ankle; no treatments performed on distal arteries within prior 12 months; and lesions balloon predilatable.
Major exclusion criteria were the following: untreated flow-limited aortoiliac disease, but subjects successfully treated (<30% residual stenosis determined angiographically) for inflow disease during the index procedure were allowed; previous stenting or surgery in target vessel; severe comorbidities (untreated coronary artery disease or congestive heart failure, severe chronic obstructive pulmonary disease, dementia, uncontrolled hypertension); Rutherford 5 or 6 classification of nonstudy limb; coagulopathy or contraindication to anticoagulants and antiplatelets; current hemodialysis or serum creatinine concentration >2.5 mg/dL; and allergies to stent graft components including heparin.
Stent graft. The GORE Viabahn Endoprosthesis with Heparin Bioactive Surface (W. L. Gore & Associates, Flagstaff, Ariz) is a flexible, self-expanding, endoluminal stent graft consisting of two components: a tubular section of expanded polytetrafluoroethylene with a heparin bioactive surface and an external nitinol structure extending along the device length.
14 Stent grafts had a proximal edge contoured to the sinusoidal stent pattern. Stent grafts were 5 to 8 mm in diameter (treating 4.0-to 7.5-mm vessels) with lengths from 2. Follow-up schedule. Participants' pre-enrollment baseline measurements were compared with follow-up values determined at 1 month, 3 months, 6 months, and 12 months after intervention. Assessments included color duplex ultrasound, ABI and TBI, Rutherford class, Vascular Quality of Life questionnaire (VascuQOL), 18 and
AEs. Plain radiographs were taken at 12 months.
Antiplatelet medication. Protocol-mandated postoperative antiplatelet regimen was 6 months of aspirin and a thienopyridine-class agent, with recommendation to maintain this regimen through 12 months. Thienopyridine requirement was waived for subjects receiving anticoagulation for other conditions.
Outcome measures. The primary efficacy outcome was 12-month primary assisted patency (PAP), defined as a stent graft that had not occluded at any time (although target lesion revascularization [TLR] could have been performed for stenosis). The PAP rate was calculated by point estimate and Kaplan-Meier (KM) estimates. Indications for TLR included but were not limited to the following: ABI worsening of >0.15 in the treated limb; Rutherford score worsening by one grade or more in the treated limb; peak systolic velocity ratio $2.5 by duplex ultrasound in the treated lesion; or emergent deterioration in physical symptoms of the treated limb (eg, blue foot).
Secondary efficacy outcomes included primary patency rate calculated for both surgical (PP-S) and interventional (PP-I) definitions; secondary patency rate; ABI and TBI; VascuQOL score; and rates of technical and clinical success, freedom from TLR (fTLR), limb salvage, and stent fracture. Survival estimates for secondary end points were calculated by KM analysis. The definition of PP-S was presence of blood flow through a device that did not require TLR to maintain or to restore blood flow. To facilitate comparison with prior endovascular studies, we defined PP-I as peak systolic velocity ratio <2.5 without TLR in treated lesions. 19 We performed subgroup analyses for PP-S and PP-I rates and fTLR based on target lesion length and device diameter (patients grouped by smallest diameter device used).
We also evaluated effects of diabetes and hypertension comorbidity, lesion calcification, smoking history, and age on PP-S and PP-I rates. Angiography, ultrasound, and radiography images were analyzed by CoreLab Black Forest, GmbH, Medical Quality Analysis Center (Bad Krozingen, Germany). Primary invasiveness outcomes were general anesthesia rate and postoperative hospitalization days. The secondary invasiveness end point was blood transfusion rate. To evaluate invasiveness parameters vs above-knee bypass operations performed in a similar cohort, we developed a comparator cohort comprising 68 of 165 consecutive Japanese patients who had synthetic graft bypass surgery between February 2002 and April 2012 in six study sites and who met similar inclusion criteria as our prospective cohort (age $20 years, Rutherford category 2 to 5 PAD, and ABI #0.9). Institutional Review Board approval was obtained from each site for using deidentified patient data.
Safety outcomes included freedom from death and major amputation of treated limb within 30 days and AE occurrence through 12 months. The VascuQOL questionnaire assessed PAD impact on daily living. 18 Statistical analysis. All efficacy and invasiveness outcome measures were calculated for the whole cohort and also for the Rutherford category 2 or 3 (R2/3) claudicants and R4/5 critical limb ischemia (CLI) subgroups in the stent graft cohort and for the whole cohort and the R2/3 subgroup in the retrospective open bypass group. Values shown are for the whole cohort, except where specified as R2/3 claudicants only. Continuous parameters are presented as mean 6 standard deviation or 95% confidence interval (CI), median, or range, as indicated, and were analyzed using unpaired t-tests or the Wilcoxon rank sum test, as indicated. Categorical variables are presented as number and percentage and were compared using Fisher exact test with 2 Â 2 contingency tables, where indicated. KM estimates were calculated for study day 365 and analyzed by log-rank test. P values < .05 were considered statistically significant. Statistical software included SAS v.9.2 and JMP v.12.2 (both from SAS Institute, Cary, NC) and Prism v.5.0 (GraphPad Software, La Jolla, Calif).
RESULTS

Patient and lesion details
After training cases, investigators treated 119 subjects between April 2012 and August 2013. Sixteen cases were deemed ineligible by the CCC, resulting in 103 cases enrolled for analysis. Ineligibility reasons were as follows: lesion <10 cm (n ¼ 4), <1 cm healthy landing zone (n ¼ 5), no patent outflow vessels to the foot (n ¼ 2), nonexpanded predilation balloon (n ¼ 2), reference vessel diameter <4 mm (n ¼ 1), one Rutherford 5 patient with active infection not evaluated by CCC before treatment, and one case with previous tibial artery treatment within preceding 12 months. Individual study sites enrolled between 2 (1.9%) and 13 (12.6%) participants. Cohort demographics were mean age of 74.2 6 7.0 years with 17.5% female (Table I) . Approximately 97% of subjects were R2/3, with the remaining 2.9% having R4/5 symptoms. Mean ABI was 0.64 6 0.12. Most frequent systemic comorbidities were arterial hypertension (88.3%), smoking history (78.6% overall; 28.2% current smokers), dyslipidemia (62.1%), and diabetes mellitus (60.2%). Mean target lesion length was 21.8 6 5.8 cm (median, 22.0 cm; range, 10.0-37.0 cm; 21.6 6 5.8 cm in R2/3 only), and mean stented length was 25.3 6 6.3 cm (median, 25.0 cm; range, 12.0-38 cm; Table II ). Proximal healthy vessel reference diameter averaged 5.2 6 0.7 mm. Runoff vessel numbers were almost uniformly distributed between one, two, and three vessels. Lesions were 15.5% TASC II type B, 72.8% type C, and 11.7% type D, most with mild or moderate calcification (71.9%) and occlusion (65.7%).
Endovascular device deployment
In total, 194 stent grafts were deployed in 103 limbs (mean, 1.9 devices/limb; Table III ). Balloon predilation was performed in all cases, according to protocol. Technical success rate (residual stenosis <30% after stent graft implantation) was 99.0%; the single exception had 30% residual stenosis. Stent grafts completely covered 100% of targeted lesions. Most frequently deployed device lengths were 15 cm (34.5%), 25 cm (26.8%), and 10 cm (17.5%). Most frequently deployed stent graft diameters were 6 mm (50.0%) and 5 mm (38.1%). 17 Inflow procedures were performed in 17 subjects (16.5%), representing 6 and 14 interventions for common and external iliac artery lesions, respectively.
Patient follow-up Of 103 enrolled patients, 100 subjects (98%) remained eligible for 12-month evaluation; 2 subjects died and 1 withdrew consent. One subject died at day 92 of respiratory failure/pneumonia, and another subject died of cerebral infarction on day 240; neither was device or procedure related.
Invasiveness and efficacy outcomes
Efficacy. The 12-month KM estimate of PAP rate was 94.1% (95% CI, 87.3-97.3; 95.9% in the R2/3 subgroup; Table IV ; Fig 1) . The 12-month whole-cohort point estimate for PAP rate was 91.0% (91/100). The KM estimated PP-S rate was 92.1% (93.9% in R2/3), PP-I rate was 88.1% (89.8% in R2/3), and secondary patency rate was 98.0% (98% in R2/3). No participant required bypass surgery through 12 months. When the 16 subjects treated but not enrolled for analysis were included, the KM estimated PP-S rate was 88.9%, PP-I rate was 82.9%, PAP rate was 94.1%, and secondary patency rate was 97.5%.
We also performed whole-cohort and R2/3 subgroup KM analyses to evaluate whether PP-S and PP-I rates were affected by target lesion length, graft stent diameter, diabetes comorbidity, and age (Fig 2) . Shorter lesions (#20 cm) had a 100% PP-S rate at 12 months, which was significantly greater than the 86.5% PP-S rate in lesions >20 cm long (P ¼ .014 all; P ¼ .030 for R2/3, not shown; Fig 2, A, left) . However, the PP-I rate showed no significant difference between these groups (P ¼ .813 all; P ¼ .389 R2/3, not shown). There was no significant difference in PP-S across different-diameter stent graphs (P ¼ .298 all; P ¼ .580 R2/3; Fig 2, B, left) . Devices sized 5, 6, and 7 mm showed significantly different PP-I rates of 80.0%, 95.5%, and 100%, respectively (P ¼ .0420); the R2/3 subgroup showed the same trend, but this was no longer significant (P ¼ .096). The 12-month PP-S rate in subjects with diabetes was 90.1% vs 95.1% in participants without diabetes, but this difference was not significant (P ¼ .365; Fig 2, C) . Age of the subject did not influence 12-month PP-S or PP-I rates in the whole cohort (Fig 2, D) or in the R2/3 subgroup (not shown). There was also no association between 12-month PP-S or PP-I rates and lesion calcification status, tibial runoff vessel number, smoking status, or presence of hypertension in the whole cohort (not shown). The whole cohort fTLR was 93.1% (95% CI, 86.1-96.7; 94.9% in R2/3 subgroup) at 12 months (Fig 3, A ; Table IV ). Lesions >20 cm long were significantly more likely to require TLR (11.7%) through 12 months than shorter pathologic processes (0.0%; P ¼ .023; Fig 3, B) . The fTLR tended to increase with increasing device diameter, but this trend was not significant (Fig 3, C) . Fifteen TLR procedures were performed in 12 individuals through the 12-month follow-up. Mean ABI immediately increased from 0.64 6 0.12 to 0.98 6 0.12 (P < .0001) at 1 month, a level maintained through 12 months (0.94 6 0.17; P < .0001). Clinical success (improvement of at least one Rutherford class) occurred in 90.9% of 99 subjects with known status at the 12-month end point. Diagnostic-quality radiographs obtained for 99 subjects at 12 months showed no stent fracture events.
Invasiveness. Because 97.1% of the stent graft cohort was staged as R2/3, we restricted invasiveness parameter statistical tests to comparing the 100 Viabahn R2/3 subjects vs the 51 of 68 open bypass R2/3 subjects, although values for all subjects are also shown in Table V . In Viabahn R2/3 subjects, no general anesthesia or transfusion was required, median procedure time was 99 minutes, median postoperative hospital stay was 2.0 days (mean, 3.4 6 2.9 days), and no subject required admission to the intensive care unit (ICU). No life-or limb-threatening intraoperative or perioperative AEs occurred. Target vessel revascularization, major amputation, or death did not occur through postoperative 30 days. The 51 of 68 retrospective Japanese bypass R2/3 subjects' mean age was 71.5 6 7.2 years; 23.5% were female, 27.5% never smoked, and 47.1% and 86.3% had comorbid diabetes and hypertension, respectively (Table V) . Bypass R2/3 subgroup freedom from general anesthesia was 23.5%, freedom from transfusion was 96.1%, median procedure time was 165 minutes, and median hospitalization duration was 11.0 days (mean 12.7 6 5.3 days), with 8% of patients admitted to the ICU. All invasiveness measures except transfusion avoidance were significantly better in the stent graft group vs bypass comparators (Supplementary Table, online only), with mean hospital stay being nearly four times longer for bypass (P < .0001 for general anesthesia avoidance, procedure time, and hospitalization duration and P ¼ .012 for ICU admission avoidance).
VascuQOL outcomes
The subjects' VascuQOL scores significantly increased in all questionnaire categories through postoperative 12 months. The total VascuQOL score increased from 58.6% 6 15.7% of maximum possible points to 72.9% 6 18.6% between baseline (4.1 6 1.1 points) and the 12-month follow-up (5.1 6 1.3 points; P < .0001).
Serious AEs
Through 12 months, 45 participants (43.7%) experienced 91 serious AEs of any causality; of these, 9 events in 7 subjects were adjudicated as possibly or probably device or procedure related. Serious AEs included five stent graft occlusions in three subjects, all occurring between 6 and 12 months; one peripheral artery restenosis event occurring at 12 months (device related); and one each of infection, postprocedure hematoma, and exacerbation of chronic renal failure that all occurred within postoperative 1 month (procedure related). The infection case was noted by the investigator to be sepsis possibly related to the procedure or to placement of a urinary catheter and resolved after penicillin administration. No cases of acute limb ischemia occurred.
DISCUSSION
This study demonstrates the safety, low invasiveness, and excellent 1-year efficacyd92% PP-S and 93% fTLR ratesdusing heparin-coated stent grafts to treat Japanese PAD patients with long (mean, 21.8 cm) SFA lesions.
The effectiveness results of this study support using heparin-coated stent grafts as an alternative to aboveknee bypass in PAD. A 2013 meta-analysis assessed four RCTs and six observational studies published through 2011 that compared open bypass with various endovascular approaches in primarily CLI subjects. 4 These investigators concluded that high-level evidence demonstrating superiority of bypass vs endovascular techniques was lacking but that endovascular should be considered a less invasive approach, particularly in patients with cardiovascular comorbidity. 76% and secondary patency rates of 83% and 86% in the stent graft and bypass groups, respectively (P > .05 for both parameters between groups). Differences were maintained through 4 years. Zeller et al 13 reported a prospective multicenter trial in Germany that evaluated stent grafts in 71 subjects with exclusively TASC II C and D long lesions (all lesions >20 cm long, 26.5 6 5.3 cm average) and showed 1-year PP-I and secondary patency rates of 67.0% and 96.7%, respectively. 11 This study showed equal or higher PP-I values compared with those previous studies. Furthermore, even with long lesions, stent graft implantation significantly improved ABI and associated VascuQOL scores through postoperative 12 months. Together, these observations support that stent grafting is a viable alternative to above-knee bypass for treating advanced SFA disease in some patients. This study's findings support interventional treatment as a less invasive treatment option than bypass. In a 2015 systematic review, van de Weijer et al 11 indicated
that open bypass has a 30-day morbidity rate of 36.8%, with wound infection rate of 7.8%, graft infection rate of 2.4%, postoperative bleeding in 7.4% of subjects (2.5% requiring reoperation), and 2.3% mortality. We used freedom from general anesthesia and postoperative hospitalization duration as invasiveness measures, comparing our stent graft cohort with a retrospectively generated control group of 68 PAD patients who previously underwent above-knee bypass in study hospitals. Stent grafts were a less invasive approach than conventional bypass surgery for those outcomes, which may provide important additional value to patients with PAD.
Stent grafts have an established record of outperforming simple balloon angioplasty and bare-metal stents for treating SFA lesions. A systematic review and meta-analysis by Zhang et al 16 analyzed five controlled studies (four RCTs [N ¼ 572] and one retrospective comparison [N ¼ 52]) that included the Viabahn device. The cumulative 1-year PP-I rate of stent grafts was greater than that of alternative endovascular interventions (relative risk, 0.63; 95% CI, 0.49-0.82; P < .001), including angioplasty 20 and bare-metal stents. 21, 22 An additional RCT report was since published that showed improved patency rates with stent graft vs angioplasty for in-stent restenotic lesions, 23 and longer term results have since been published showing increased patency vs bare-metal stents. 24 Racial and ethnic disparities have been investigated for possible effect on outcomes after endovascular intervention. 25 In a multinational trial comparing a drug-eluting stent with angioplasty for PAD, Ohki et al 26 found no significant differences between Japanese (n ¼ 27) and non-Japanese subgroups (n ¼ 211) in event-free survival, patency, fTLR, and stent fracture rates. A subsequent 2016 postmarket surveillance report of 907 Japanese patients reported a 12-month PP-I rate of 86.4% with fTLR at 91.0%, in lesions averaging 14.7 6 9.7 cm. 27 Furthermore, the multinational trial of Ohki et al 28 assessed a bare nitinol self-expanding stent in SFA lesions (mean length, 8.4 6 4.1 cm) of 261 subjects, 60 from Asian nations, and reported similar PP-I rate (83%) and fTLR (87%) outcomes in Asian vs U.S. subgroups. The patency rates of this study are higher than in prior multicenter, prospective Viabahn stent graft
Kaplan-Meier (KM) estimates of primary, primary assisted, and secondary patency in Viabahn stentgrafted lesions at 12 months after intervention. Primary patency-surgical (PP-S), primary patency using the definition typically employed in surgical bypass studies, that is, presence of blood flow through a device that did not require target lesion revascularization (TLR) to maintain or to restore blood flow. Primary patencyinterventional (PP-I), primary patency using the definition typically used in interventional studies, that is, peak systolic velocity ratio <2.5 across the treated lesion. CI, Confidence interval.
Fig 2.
Primary patency subgroup analyses of Viabahn stent-grafted lesions through 12 months after intervention by Kaplan-Meier (KM) analysis. Primary patency was evaluated using both the clinical definition typically employed to track outcomes of surgical bypass (primary patency-surgical [PP-S], left column, that is, hemodynamic blood flow through a device that did not require a target lesion revascularization [TLR] to maintain or to restore blood flow) and the ultrasound-determined definition of patency as peak systolic velocity ratio <2.5 that is commonly reported in endovascular interventional studies (primary patency-interventional [PP-I], right column). Longer lesions were significantly correlated to decreased PP-S (A), and smaller diameter stent grafts were significantly associated with decreased PP-I (B). Primary patency was unaffected by both diabetes comorbidity (C) and age of the subject (D). There was no association between the primary patency rate at postoperative 12 months and lesion calcification status, number of treated tibial runoff vessels, smoking status, or hypertension comorbidity (not shown). CI, Confidence interval.
implantation studies, 13, [20] [21] [22] [23] [24] 29 and this is unlikely to be due to ethnicity of the subjects. 26, 28 At the time of study enrollment, subanalyses of another stent graft trial indicated that restricting stent oversizing to #20% at the device's proximal edge significantly increased PP-I (88% vs 70% for oversized; P ¼ .047). 29 This confirmed observations from earlier porcine experiments showing a linear relationship between nitinol stent oversizing and neointimal proliferation and luminal stenosis severity 6 months after implantation. 30 Investigators in the present Japanese study conscientiously selected stent grafts that were below this 20% oversizing cutoff, guided by quantitative angiography and intravascular ultrasound. The 12-month PP-I rate in this study is identical to that in the properly sized subgroup analysis of the Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER) study. 29 Thus, careful sizing of stent grafts appears to improve outcomes through postoperative 12 months. Lesion length is a proxy measurement for disease severity, and decreased patency in longer vs shorter lesions has been reported in previous stent graft studies, although these differences did not attain statistical significance. 21, 29 In this study, we observed lower 12-month primary patency rates in lesions >20 cm vs those #20 cm long. Still, a 12-month PP-S rate of 86.5% (PP-I rate of 84.8%) in long lesions compares favorably with the mean 72% primary patency rate at 12 months reported in a systematic review of three RCTs and four observational studies of SFA open reconstruction. 4 Improved PP-I was significantly correlated with larger device and target vessel diameter. This could be explained by the greater relative impact of a given thickness of intimal neoplasia at the stent graft edge in smaller vs larger vessels. Although there was no observed impact of device diameter on PP-I in the VIPER study using heparin-coated stent grafts, 29 it is possible that excessive oversizing (>20%) with the majority of stent grafts (57/95 measurable devices) obscured this relationship.
In this study, we observed an 80.0% PP-I rate in 5-mm stent grafts. This is similar to the results for 5-mm heparin-coated stent grafts in the VIPER trial 29 and likely represents a very good solution for patients with smaller diseased vessels. Although low-level evidence suggests that diabetes comorbidity may be associated with worse outcomes after either endovascular or bypass intervention, 31, 32 this correlation may be restricted to insulin dependency. 33 Diabetes was not statistically correlated with primary patency in this study. We also found no correlation between postoperative patency and age of the subject, lesion calcification status, runoff vessel number, smoking history, or hypertension status. Primary study limitations were its single-arm design, relatively small sample size (N ¼ 103), and inclusion of mainly claudicants, which limits generalizability across CLI patients. Only 1-year results are reported here; however, 2-year efficacy results will be collected, and AE assessment and fracture analysis will be conducted through 5 years. Longer term multinational RCTs such as the Surgical versus Percutaneous Bypass (SuperB) study, 34 which directly compares outcomes of stent graft implantation vs bypass surgery for treating long SFA lesions, will provide essential confirmation of our findings in diverse populations. Device limitations include the necessity for at least one patent runoff vessel and unsuitability for across-the-knee applications. A prior single-center retrospective series showed less favorable results with a population that did not adhere to these limitations, had a larger proportion of CLI patients, and included in-stent restenosis. 35 Nonetheless, our results demonstrate that stent grafts can safely provide improvement to patients with extensive PAD through 1 year of follow-up 
CONCLUSIONS
Stent grafting for above-knee PAD is safe and results in excellent 1-year efficacy outcomes, precludes general anesthesia necessity, and reduces postoperative hospitalization duration vs conventional bypass. Endovascular stent grafting of long, complicated SFA lesions is a minimally invasive procedure that appears to be a suitable alternative to open bypass surgery for treating advanced above-knee PAD. 
